stockrowCorcept Therapeutics Incorporated
CORT Healthcare Biotechnology
Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.
- Revenue
- +64.0%
- EPS
- +525.8%
- Free cash flow
- +161.0%
Quarter to September 2026, against a year earlier
Follow CORT
Alert me
Corcept Therapeutics Incorporated (CORT) Gross margin
Corcept Therapeutics Incorporated's gross margin over the twelve months to 30 September 2026 was 98.5%, up 0.2 percentage points from fiscal 2025 (98.3%). Over the past ten years it has ranged from 97.3% (fiscal 2015) to 98.7% (fiscal 2023); the current reading is higher than 55% of that period. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 98.3% | (0.09) |
| FY2024 | 98.4% | (0.27) |
| FY2023 | 98.7% | 0.00 |
| FY2022 | 98.7% | 0.10 |
| FY2021 | 98.6% | 0.14 |
| FY2020 | 98.4% | 0.22 |
| FY2019 | 98.2% | 0.28 |
| FY2018 | 97.9% | 0.15 |
| FY2017 | 97.8% | 0.30 |
| FY2016 | 97.5% | 0.18 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 98.7% | 0.24 |
| Jun 2026 | 98.4% | 0.16 |
| Mar 2026 | 98.3% | (0.49) |
| Dec 2025 | 98.7% | 0.95 |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 100.0% |
| PRAX Praxis Precision Medicines, Inc. compare | 100.0% |
| PTGX Protagonist Therapeutics, Inc. compare | 100.0% |
| SYRE Spyre Therapeutics, Inc. compare | 100.0% |
| CORT Corcept Therapeutics Incorporated | 98.5% |
| KRYS Krystal Biotech, Inc. compare | 94.3% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 91.0% |
| CYTK Cytokinetics, Incorporated compare | 0.00% |
| ABVX Abivax SA Sponsored ADR compare | 0.00% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on CORT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement